Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.60 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 9/20 | 0.50 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | GRK5 | P34947 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679030 | 0.89 | PRKD3 (0.65) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679170 | 0.86 | FYN (0.58) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679101 | 0.85 | PRKD3 (0.81) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679473 | 0.85 | GRK5 (0.64) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1678982 | 0.83 | PRKD3 (0.53) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679717 | 0.82 | MAP4K4 (0.53) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679695 | 0.79 | FYN (0.62) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679442 | 0.78 | PRKD3 (0.73) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679495 | 0.78 | PRKD3 (0.83) | PRKD3PRKD1PRKD2MAP4K4FYN | |
| SCHEMBL1679783 | 0.78 | KMT2A (0.51) | PRKD3PRKD1PRKD2MAP4K4FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | PRKD3 38/4885PRKD1 33/4885PRKD2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.